Attached files
file | filename |
---|---|
8-K - FORM 8-K - MYLAN INC. | l41108e8vk.htm |
Exhibit 99.1
Mylan Announces Pricing of Senior Notes
PITTSBURGH, November 9, 2010 Mylan Inc. (Nasdaq: MYL) today announced the pricing in the private
placement of senior notes announced earlier today. Mylan priced $800 million aggregate principal
amount of 6.0% Senior Notes due 2018 at an issue price of 98.450%. Mylan intends to use the
gross proceeds to prepay term loans thereby reducing senior secured leverage and extending the
maturity profile of its outstanding indebtedness. Subject to customary closing conditions, the sale
of the notes is expected to close on or about November 24, 2010.
The notes will be sold only to qualified institutional buyers in the United States in reliance on
Rule 144A under the Securities Act of 1933, and outside the United States to non-U.S. persons in
reliance on Regulation S under the Securities Act. The notes
have not been and will not be registered under the
Securities Act, and may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. This press release shall not constitute an
offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale
of securities mentioned in this press release in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such
state.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and
provides products to customers in more than 140 countries and territories. The company maintains
one of the industrys broadest and highest quality product portfolios supported by a robust product
pipeline; operates one of the worlds largest active pharmaceutical ingredient manufacturers; and
runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more
information, please visit www.mylan.com.
Forward-Looking Statements
This press release includes statements that constitute forward-looking statements. These
statements are made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause or contribute to such differences include, but are not limited
to Mylans failure to consummate the private placement or to utilize the proceeds of such placement
as described in this press release. These cautionary statements should be considered in connection
with any subsequent written or oral forward-looking statements that may be made by Mylan or by
persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please
refer to the cautionary statements and risk factors set forth in Mylans Quarterly Report on Form
10-Q for the period ended September 30, 2010 and in its other periodic filings made with the SEC
from time to time.